INM:NASDAQ, InMed Pharmaceuticals Inc.
Why INM stock rose on November 6
InMed Pharmaceuticals Inc. rose 19.6%
on Friday, November 6, 2026, on 27,154 shares, 3.6 times its average daily volume.
Headlines around the move:
INM stock overview
InMed Pharmaceuticals Inc. (INM:NASDAQ) closed at $15.56 on November 6, 2026,
up 19.65% on the day.
The stock trades 33.2% below its 52-week high of $23.30
and 170.6% above its 52-week low of $5.75.
Over the past year, it gained 29.7%.
InMed Pharmaceuticals Inc. is part of the Health Care sector.
Key figures
- Price
- $15.56
- Day change
- +19.65%
- Volume
- 27,154
- Average volume
- 7,623
- Market cap
- 8M+
- 52-week range
- $5.75 – $23.30
- 50-day average
- $13.94
- 200-day average
- $12.20
Price action over the past year
In 252 trading sessions since November 20, 2025, INM closed higher on 96 days (38%).
Its best day was May 19, 2026 (+134.95%) and its worst was November 5, 2026 (-24.51%).
The stock moved 10% or more in a single session 13 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
INM news
-
Nov 9, 2026:
Mentari Therapeutics to Present at Upcoming Investor Conferences
-
Nov 9, 2026:
Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing
-
Nov 9, 2026:
Fox-Roku's $22B Deal, A New Nasdaq Biotech And A $25B Chemicals Tie-Up: Deals Investors Are Watching
-
Nov 9, 2026:
Fox-Rokus $22B Deal, A New Nasdaq Biotech And A $25B Chemicals Tie-Up: Deals Investors Are Watching
-
Nov 6, 2026:
InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics
-
Nov 5, 2026:
InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"
-
Nov 4, 2026:
InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation
-
Nov 3, 2026:
InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based pre-clinical stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based therapies combined with drug delivery systems. It is focused on the treatment of diseases including pain and inflammation, dermatology, Orofacial Pain, Glaucoma, ocular, CNS, respiratory, metabolic diseases, and others.
Similar stocks
Find more stocks like INM with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.